Article Text

Download PDFPDF
β-blockers associated with reduced all-cause mortality in COPD
  1. Donald P Tashkin
  1. David Geffen School of Medicine at UCLA, Department of Medicine, Los Angeles, California, USA
  1. Correspondence to Donald P Tashkin
    David Geffen School of Medicine at UCLA, Department of Medicine, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA; dtashkin{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlAbstract/FREE Full Text


Chronic obstructive pulmonary disease (COPD) is currently recognised as an inflammatory disease associated with significant extrapulmonary effects and important comorbidities, including ischaemic heart disease and heart failure.1 Despite ample evidence of the benefits of β-blockers in hypertension, ischaemic heart disease and congestive heart failure, use of β-blockers is >50% lower in heart failure patients with than without COPD,2 probably because of concern regarding the possibility of bronchospasm provoked by β-blockers in patients with underlying obstructive lung disease, despite evidence to the contrary.3 In view of the compelling evidence demonstrating beneficial effects of β-blockers in cardiovascular disease (CVD), including improved …

View Full Text


  • Competing interests None.